Diagnosing Cushing's Syndrome
Initial Screening Tests for Hypercortisolism
- The Endocrine Society recommends late-night salivary cortisol (LNSC) as a highly sensitive (95%) and specific (100%) test for diagnosing Cushing's syndrome, with at least 2-3 samples collected on consecutive days 1, 2
- The American Association of Clinical Endocrinologists suggests 24-hour urinary free cortisol (UFC) as a measure of overall cortisol production, with high sensitivity (89%) and specificity (100%), and recommends collecting at least 2-3 samples to account for variability 1, 2
- The European Society of Endocrinology recommends an overnight dexamethasone suppression test (DST) to measure the inability to suppress cortisol with dexamethasone, with a serum cortisol <1.8 μg/dL (50 nmol/L) at 8 AM after 1 mg dexamethasone at midnight indicating a normal response 3, 2
Blood Tests for Determining Etiology
- The American College of Endocrinology states that morning plasma ACTH level is essential to differentiate ACTH-dependent from ACTH-independent causes, with normal/elevated ACTH (>5 ng/L or >1.1 pmol/L) suggesting ACTH-dependent Cushing's syndrome and low/undetectable ACTH indicating ACTH-independent Cushing's syndrome 1, 3
- The Endocrine Society recommends a CRH stimulation test in ACTH-dependent cases, with a ≥20% increase in cortisol from baseline during CRH testing supporting pituitary origin 1, 4
Special Considerations
- The American Association of Clinical Endocrinologists notes that pseudo-Cushing's states, such as severe obesity, uncontrolled diabetes, depression, and alcoholism, can cause false-positive results 3, 5
Diagnostic Algorithm
- The European Society of Endocrinology recommends ruling out exogenous glucocorticoid use and performing 2-3 first-line screening tests based on clinical suspicion, with high suspicion requiring multiple tests (LNSC, UFC, DST) and low suspicion starting with LNSC 3
- The American College of Endocrinology suggests measuring plasma ACTH if screening tests are abnormal, with normal/high ACTH proceeding with pituitary MRI and low ACTH proceeding with adrenal imaging 3
- The Endocrine Society recommends considering bilateral inferior petrosal sinus sampling (BSIPSS) for ACTH-dependent cases with equivocal findings 1, 4
Diagnosing Cushing's Syndrome
First-Line Screening Tests
- Multiple LNSC collections may be easier for patient compliance compared to 24-hour urine collection, according to The Lancet Diabetes and Endocrinology 6
- DST may be less useful in women taking estrogen-containing oral contraceptives, as noted by The Lancet Diabetes and Endocrinology 6
- Measuring dexamethasone levels along with cortisol improves test interpretability, as reported by The Lancet Diabetes and Endocrinology 6
Diagnostic Algorithm
- In children and adolescents, consider screening only if weight gain is inexplicable and combined with either decreased height standard deviation score or height velocity, as recommended by Nature Reviews Endocrinology 7
- For high clinical suspicion, perform multiple tests (LNSC, UFC, DST), as suggested by The Lancet Diabetes and Endocrinology 6
- If any test is abnormal, repeat 1-2 screening tests to confirm, according to The Lancet Diabetes and Endocrinology 6
- If all tests are normal, Cushing's syndrome is unlikely, as stated by The Lancet Diabetes and Endocrinology 6
Special Considerations
- Severe obesity can cause false-positive results, as noted by The Lancet Diabetes and Endocrinology 6
- Consider cyclic Cushing's syndrome in cases with inconsistent results, as recommended by The Lancet Diabetes and Endocrinology 6
Cushing's Syndrome Diagnosis and Evaluation
Initial Evaluation and Screening
- The American College of Endocrinology recommends excluding iatrogenic Cushing's syndrome by thoroughly reviewing all glucocorticoid use before any biochemical testing, as failure to do so leads to unnecessary testing without patient benefit 8, 9
- For patients with intermediate to high clinical suspicion, the Endocrine Society suggests performing 2-3 first-line screening tests, including late-night salivary cortisol, 24-hour urinary free cortisol, and overnight 1 mg dexamethasone suppression test, to confirm the diagnosis of Cushing's syndrome 8
- Measuring dexamethasone levels along with cortisol improves the interpretability of the overnight 1 mg dexamethasone suppression test 8
Interpretation of Screening Results and Further Evaluation
- If any screening test is abnormal, the American Thoracic Society recommends repeating 1-2 screening tests to confirm the diagnosis of Cushing's syndrome 9
- If all tests are normal and clinical suspicion is low to moderate, Cushing's syndrome is unlikely, but if clinical suspicion remains high, referral to an endocrinologist for further evaluation is recommended 9
- For ACTH-dependent Cushing's syndrome, the Endocrine Society suggests performing pituitary MRI to detect pituitary adenoma, with a sensitivity of 63% and specificity of 92% 8
- Bilateral inferior petrosal sinus sampling (BIPSS) is recommended if pituitary MRI is negative or equivocal, with diagnostic criteria of central-to-peripheral ACTH ratio ≥2:1 before stimulation and ≥3:1 after CRH stimulation 8
Special Populations
- In patients with lung cancer presenting with symptoms suggestive of Cushing's syndrome, such as moon facies, acne, and purple striae, the American College of Chest Physicians recommends suspecting paraneoplastic Cushing's syndrome 9
- Skin hyperpigmentation is usually more prominent with ectopic ACTH, and weight loss occurs in about 10% of cases associated with small cell lung cancer 9
Late Night Salivary Cortisol Collection for Cushing's Syndrome Diagnosis
Physiologic Basis
- The diagnostic utility of LNSC relies on the principle that patients with Cushing's syndrome lose their normal circadian nadir of cortisol secretion that occurs at night, according to The Lancet Diabetes and Endocrinology 10
- The cortisol nadir is tightly entrained to sleep onset, so sampling at the patient's usual bedtime rather than strictly at midnight may decrease false positive results, as recommended by The Lancet Diabetes and Endocrinology 10
Collection Technique
- Timing: Collect saliva samples at the patient's usual bedtime (typically 11 PM-midnight) when cortisol should be at its nadir, as suggested by The Lancet Diabetes and Endocrinology 10
- Number of samples: At least 2-3 samples collected on consecutive days are required due to test variability and to detect cyclic Cushing's syndrome, according to The Lancet Diabetes and Endocrinology 10
Diagnostic Performance
- Specificity: 93-100%, the highest among all first-line screening tests for Cushing's syndrome, as reported by The Lancet Diabetes and Endocrinology 10
Interpretation of Results
- Mild disease: Patients with mild Cushing's syndrome may have LNSC values just above the upper limit of normal, as noted by The Lancet Diabetes and Endocrinology 10
- Cyclic disease: Multiple sequential LNSC measurements are particularly useful for detecting cyclic Cushing's syndrome, where patients exhibit weeks to months of normal cortisol secretion interspersed with episodes of excess, according to The Lancet Diabetes and Endocrinology 10
Critical Contraindications and Pitfalls
- Absolute contraindication: LNSC should NOT be performed in night-shift workers or anyone with disrupted day/night cycles, as stated by The Lancet Diabetes and Endocrinology 10
- Topical hydrocortisone contamination: Topical steroid preparations can contaminate samples, particularly when mass spectrometry is used, as warned by The Lancet Diabetes and Endocrinology 10
- Mass spectrometry vs. immunoassay: Mass spectrometry can detect both cortisol and cortisone, avoiding contamination from topical hydrocortisone, and offers better sensitivity but reduced specificity compared to immunoassay, as reported by The Lancet Diabetes and Endocrinology 10
Clinical Application Algorithm
- Exclude contraindications: Verify patient does not work night shifts and has regular sleep-wake cycles, as recommended by The Lancet Diabetes and Endocrinology 10
- If results are inconsistent: Consider cyclic Cushing's syndrome and perform extended monitoring with multiple periodic sequential LNSC measurements, as suggested by The Lancet Diabetes and Endocrinology 10
Serum Cortisol and ACTH Measurements in the Diagnosis of Cushing’s Syndrome
Role of Serum Cortisol in the Diagnostic Algorithm
- Serum cortisol is not a first‑line screening test for Cushing’s syndrome; its primary utility is at defined steps of the work‑up, such as measuring ACTH to define etiology and using midnight serum cortisol when late‑night salivary cortisol cannot be obtained. 11
ACTH Measurement for Etiology Determination
- After confirming hypercortisolism with any first‑line screening test, a single morning plasma ACTH measurement is essential to distinguish ACTH‑dependent from ACTH‑independent disease. 11
- Low or undetectable ACTH (e.g., < 5 ng/L or < 1.1 pmol/L) indicates an ACTH‑independent (adrenal) source and directs clinicians to obtain adrenal imaging (CT or MRI). 11
- Normal or elevated ACTH suggests an ACTH‑dependent source (pituitary or ectopic) and prompts pituitary MRI as the next imaging step. 11
Midnight Serum Cortisol as an Alternative Screening Test
- In hospitalized patients where late‑night salivary cortisol is impractical, midnight serum cortisol can serve as an alternative screening test; a value < 1.8 µg/dL (≈ 50 nmol/L) in a sleeping individual is considered normal. 11
Adjunctive Dexa Level Measurement in the DST
- Simultaneous measurement of dexamethasone levels with serum cortisol during the overnight 1‑mg dexamethasone suppression test enhances interpretability by confirming adequate drug absorption and ruling out false‑positive results due to abnormal dexamethasone metabolism. 11
Pseudo‑Cushing’s States and False‑Positive Results
- Conditions such as severe obesity, major depression, chronic alcoholism, and uncontrolled diabetes can produce modest cortisol elevations that mimic Cushing’s syndrome, leading to false‑positive screening outcomes. 11
Confirmation of Abnormal Screening Tests
- When an initial screening test (late‑night salivary cortisol, 24‑hour urinary free cortisol, or DST) is abnormal, repeat testing (1–2 additional assays) is recommended to confirm hypercortisolism before proceeding to ACTH measurement. 11
Evidence‑Based Approach to Screening and Diagnosis of Cushing Syndrome
First‑Line Biochemical Screening
- In patients with clinical suspicion of Cushing syndrome, at least two to three first‑line screening tests—late‑night salivary cortisol (LNSC), 24‑hour urinary free cortisol (UFC), and/or the overnight 1 mg dexamethasone suppression test (DST)—should be performed to confirm hypercortisolism. 12
- LNSC should be collected on 2–3 consecutive evenings at the patient’s usual bedtime (≈11 pm–midnight) to assess loss of the normal circadian cortisol rhythm. 12
- LNSC is contraindicated in individuals who work night shifts or have disrupted sleep‑wake cycles because the test relies on a normal nocturnal cortisol nadir. 12
- LNSC is preferred for patient compliance, as multiple short‑duration saliva collections are easier to obtain than a 24‑hour urine collection. 12
- UFC testing requires 2–3 separate 24‑hour urine collections to accommodate day‑to‑day variability in cortisol excretion. 12
- The overnight 1 mg DST is the preferred screening test for patients with irregular sleep schedules or shift‑work patterns, because it does not depend on a fixed bedtime collection. 12
- The DST may yield false‑positive results in women receiving oral estrogen therapy, which raises cortisol‑binding globulin and can blunt cortisol suppression. 12
- Simultaneous measurement of serum dexamethasone concentration during the DST is recommended to verify adequate drug absorption and to exclude false‑positive results caused by rapid metabolism or CYP3A4‑inducing medications. 12
Interpretation, False‑Positives, and Pseudo‑Cushing
- False‑positive screening results can occur in severe obesity, uncontrolled diabetes, major depressive disorder, chronic alcoholism, and pregnancy; these conditions constitute “pseudo‑Cushing” states that mimic mild hypercortisolism. 12
- Pseudo‑Cushing states (e.g., depression, alcoholism, severe obesity, uncontrolled diabetes) may produce modest elevations in cortisol tests and should be considered when interpreting abnormal screening results. 12
- When mild hypercortisolism is detected in the context of a possible pseudo‑Cushing state, clinicians should treat the underlying condition and repeat biochemical testing after 3–6 months of follow‑up. 12
Dynamic Testing and Localization Pitfalls
- Bilateral inferior petrosal sinus sampling (BIPSS) must not be used to diagnose hypercortisolism; it is reserved solely for localizing the source of ACTH after hypercortisolism has been biochemically confirmed. 12
- In patients with cyclic Cushing syndrome, active hypercortisolism should be verified with a screening test (LNSC, UFC, or DST) immediately before performing BIPSS or other dynamic localization studies. 12
- A single abnormal screening test is insufficient for diagnosis; repeat testing of 1–2 screening modalities is essential to minimize false‑positive diagnoses. 12
Diagnosis and Management of a Positive Dexamethasone Suppression Test with Normal ACTH
Diagnostic Interpretation
- A positive dexamethasone suppression test (failure to suppress cortisol) together with a normal ACTH level most strongly indicates ACTH‑independent Cushing’s syndrome originating from an adrenal lesion such as an adenoma or adrenocortical carcinoma. 13, 14
- In early or mild adrenal disease the autonomous cortisol production may not yet have fully suppressed pituitary ACTH, resulting in a “normal” ACTH despite a positive DST. 13, 14
- Pseudo‑Cushing’s states—including obesity, major depression, anxiety disorders, and alcohol‑use disorder—can produce a similar biochemical pattern of cortisol excess with normal ACTH. 15
- Polycystic ovary syndrome can also be associated with a pseudo‑Cushing’s‑like profile. 13
Imaging Evaluation
- Computed tomography (CT) is the first‑line imaging modality for evaluating a suspected adrenal source of cortisol excess because it is widely available and cost‑effective. 13
- Imaging features that raise suspicion for adrenocortical carcinoma (ACC) include a mass larger than 4 cm, irregular margins, heterogeneous enhancement, and unenhanced Hounsfield units > 10. 13, 14
- When such suspicious features are present, ACC must be considered and appropriate oncologic referral arranged. 13, 14, 16
Hormonal Profiling (ESMO Guidelines)
- The European Society for Medical Oncology (ESMO) recommends a comprehensive steroid panel for any adrenal mass with cortisol excess, including serum DHEA‑S, 17‑OH‑progesterone, androstenedione, testosterone, and 17‑β‑estradiol (in men and post‑menopausal women). 13, 14, 16
- A 24‑hour urine steroid metabolite analysis should be added when available to further characterize the lesion. 13
- Plasma and urine metanephrines are advised to exclude pheochromocytoma, although they may be omitted if ACC is already clearly established. 13, 14
- This “hormonal fingerprint” aids in distinguishing benign adenomas (which show mature steroidogenesis) from ACC (which typically displays immature steroid patterns). 13, 14
Pseudo‑Cushing’s Considerations
- Oral estrogen therapy can cause false‑positive DST results by raising cortisol‑binding globulin and reducing free cortisol suppression. 15
- Cyclic Cushing’s syndrome may produce fluctuating ACTH levels; extended monitoring with multiple sequential late‑night salivary cortisol measurements is recommended in such cases. 15
Referral and Management Algorithm
- Confirm DST integrity – check for drug interactions and, if possible, measure serum dexamethasone levels.
- Repeat first‑line screening (2–3 late‑night salivary cortisol samples and/or 24‑hour urinary free cortisol collections) to verify true hypercortisolism.
- Exclude pseudo‑Cushing’s by assessing for obesity, depression, alcoholism, and related conditions; treat underlying disorders and repeat testing after 3–6 months. 15
- Proceed to adrenal CT/MRI once hypercortisolism is confirmed, regardless of ACTH level. 13, 14
- Perform comprehensive steroid profiling as outlined by ESMO to guide diagnosis and follow‑up. 13, 14, 16
- Refer to an experienced adrenal surgeon when imaging demonstrates an adenoma or a mass suspicious for ACC. 13, 14
- Immediate endocrinology referral is warranted for any adrenal lesion >4 cm or with malignant imaging characteristics. 13
Screening and Diagnostic Approach for Cushing’s Syndrome in Patients with Moon Face and Weight Gain
Clinical Presentation
- Moon‑facial rounding combined with central weight gain is one of the most specific physical findings for Cushing’s syndrome and should prompt immediate biochemical screening. 17, 18, 19
Pre‑Test Considerations
- Prior to any cortisol testing, obtain a thorough medication history to rule out all sources of exogenous glucocorticoids (oral, inhaled, topical, intra‑articular, or over‑the‑counter). Failure to exclude iatrogenic exposure leads to unnecessary testing. 18, 19
First‑Line Screening Tests (All Three Recommended)
Overnight 1‑mg Dexamethasone Suppression Test
- Protocol – Administer 1 mg dexamethasone orally at 23:00–00:00 h; draw serum cortisol at 08:00 h the next morning. 18, 19
- Enhanced accuracy – Simultaneously measure dexamethasone concentration to confirm adequate drug absorption and to identify rapid metabolism that can cause false‑positive results. 18, 19
24‑Hour Urinary Free Cortisol (UFC)
- Protocol – Collect 2–3 separate 24‑hour urine specimens on different days to account for intra‑individual variability. 18, 19
Late‑Night Salivary Cortisol (LNSC)
- Protocol – Obtain saliva at the patient’s usual bedtime (≈23:00–00:00 h) on 2–3 consecutive nights; avoid night‑shift workers or anyone with disrupted sleep‑wake cycles. 18
Interpretation Algorithm
- Abnormality in ≥2 screening tests → Measure 9 AM plasma ACTH to differentiate ACTH‑dependent from ACTH‑independent disease. 18, 19
Pseudo‑Cushing’s States
- Severe obesity can produce biochemical patterns that mimic Cushing’s syndrome and should be considered when interpreting abnormal screening results. 19
Paraneoplastic (Ectopic ACTH) Cushing’s Syndrome
- In patients with known or suspected lung cancer (especially small‑cell carcinoma or bronchial carcinoid), moon‑facial rounding with weight gain raises suspicion for ectopic ACTH production. 20, 21
- Characteristic associated findings:
Additional Laboratory Evaluation
- Order thyroid‑stimulating hormone (TSH) and free thyroxine (Free T4) to exclude hypothyroidism, which can also cause weight gain and facial puffiness (though not true moon facies). This is especially relevant when patients exhibit cold intolerance, constipation, or delayed ankle reflexes. 17, 18, 19